Anthem Biosciences Limited, a prominent innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organisation (CRDMO), made its much-anticipated debut on the Indian stock exchanges, BSE and NSE, today, July 21, 2025. The initial public offering (IPO) generated significant buzz, attracting robust investor interest and ultimately listing at a healthy premium.
Anthem Biosciences Share Price & IPO Details:
- Issue Period: July 14, 2025, to July 16, 2025
- Price Band: ₹540 to ₹570 per equity share
- Lot Size: 26 shares
- Total Issue Size: Approximately ₹3,395 crore, entirely an Offer for Sale (OFS) of 5.96 crore equity shares.
- Allotment Date: July 17, 2025
- Listing Date: July 21, 2025 (BSE and NSE)
Strong Subscription Across Categories:
The Anthem Biosciences IPO witnessed overwhelming demand from all investor categories, highlighting the market’s confidence in the company’s prospects. The IPO was subscribed a phenomenal 67.42 times overall.
- Qualified Institutional Buyers (QIBs): This segment showed exceptional interest, subscribing an impressive 192.80 times their allotted portion.
- Non-Institutional Investors (NIIs): NIIs also participated strongly, with a subscription rate of 44.70 times.
- Retail Individual Investors (RIIs): The Retail investors’ portion was subscribed 5.98 times, indicating broad public interest.
- Employee: The employee portion was subscribed 6.99 times.
Grey Market Premium (GMP) and Listing Expectations:
Prior to its listing, Anthem Biosciences’ IPO’s Grey Market Premium (GMP) indicated a strong debut. The GMP, which reflects the premium at which shares traded in the unofficial market, was reported around ₹179 on listing day. Based on the upper end of the IPO price band of ₹570, this suggested an estimated listing price of approximately ₹749 per share, a potential gain of around 31.40%.
Listing Day Performance:
Anthem Biosciences made a solid debut on the bourses, reinforcing the positive sentiment from the grey market.
- On the BSE, the stock listed at ₹723.10, a premium of approximately 26.86% over the issue price of ₹570.
- On the NSE, the shares opened at ₹723.05, marking a 26.85% gain over the issue price.
The stock further rallied post-listing, touching highs of ₹746.70 on the BSE and ₹747 on the NSE. This robust performance on the first day of trading has rewarded investors who participated in the IPO with significant listing gains.
About Anthem Biosciences:
Founded in 2006, Anthem Biosciences is a leading CRDMO company offering end-to-end services in drug discovery, development, and manufacturing. The company is known for its innovation-driven approach, incorporating advanced technological solutions across various modalities. It also specialises in manufacturing and selling complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. With a strong global clientele and a focus on green chemistry methods, Anthem Biosciences has established itself as a key player in the pharmaceutical industry.
Explore More News & Updates
Stay informed with the latest news, trends, and insights on MeritNews24 – your trusted source for reliable and up-to-date information.
